Estring vaginal ring
Estring is a silicone vaginal ring that releases low-dose estradiol locally over 90 days to treat the vaginal dryness and urinary symptoms of menopause.
How it works
Estring releases a small, continuous dose of estradiol directly to vaginal tissue over a 90-day period. Its distinguishing feature is the dosing interval: unlike tablets or inserts that require twice-weekly application after the initial period, Estring is inserted once and replaced every three months. This makes it practical for people who find frequent applications difficult to maintain. Systemic absorption is minimal — even lower than some vaginal tablets — keeping serum estradiol within postmenopausal ranges throughout the 90-day period.
Estring is indicated for vaginal dryness and urinary symptoms of the genitourinary syndrome of menopause (GSM). It is not intended as primary therapy for systemic menopause symptoms (hot flashes, sleep disruption) — those require systemic hormone therapy. The ring can occasionally be felt during intercourse, but this is uncommon; it can be removed for intercourse and reinserted, though this is generally not necessary. A progestogen is not required with Estring due to its minimal systemic absorption.
How to track Estring vaginal ring
- Vaginal dryness and discomfort level — the primary symptom target; rate on a consistent scale from week one of the 90-day cycle.
- Dyspareunia if applicable — track frequency and severity separately from general dryness.
- Urinary urgency, frequency, and UTI episodes — a key secondary benefit of vaginal estrogen that should be tracked separately.
- Ring presence and comfort — logging any episodes where the ring was felt, repositioned, or removed helps identify whether fit is appropriate.
- Ring replacement dates — each ring lasts 90 days; logging the replacement date is essential for maintaining the continuous treatment effect.
- Rate vaginal symptoms from day one of the first ring — the 90-day log shows the full arc of tissue response and gives your physician a complete picture at the replacement visit.
- Track urinary urgency and UTI episodes with dates, not just hot flash-related symptoms — vaginal estrogen's urinary benefits are well-documented and worth measuring.
- Note the insertion date and 90-day replacement date in your log — missing the replacement by more than a few days creates a gap in local estradiol delivery.
- If you remove the ring for intercourse, log the removal and reinsertion times — extended removal reduces local estradiol levels and may affect symptom control.
- Compare symptom ratings at weeks four, eight, and twelve of each 90-day cycle — if symptoms worsen toward the end of the ring period, that suggests end-of-cycle depletion worth discussing.
Questions to ask your physician
- My vaginal dryness rating at the start of this ring cycle was [X]. At week [N], my current rating is [Y]. Is that trajectory consistent with expected 90-day tissue response?
- I've been tracking urinary urgency — here is the episode count over the [N] weeks since insertion. Is the improvement within the expected range for this product?
- My symptom log shows [pattern] in the final two to three weeks before ring replacement. Does that end-of-cycle pattern suggest the ring is not lasting the full 90 days?
- I've noted [X] occasions when I removed the ring, with removals lasting [duration]. Could those gaps explain any symptom fluctuation I logged?